• Regulatory

FDA approves AstraZeneca’s Saphnelo for SLE

pharminent April 28, 2026

• Clinical Data

Oruka surges as long-acting psoriasis drug shows early promise

pharminent April 27, 2026

• Regulatory

Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA

pharminent April 27, 2026

• Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

• Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

pharminent April 27, 2026

• Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

• M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

• Regulatory

Novartis secures pair of regulatory wins for skin disease and malaria treatments

pharminent April 27, 2026

• Other

New NIHR-funded TRC for Parkinson’s disease

pharminent April 27, 2026

• Commercial

Lilly falls on slower start for Foundayo versus Wegovy

pharminent April 27, 2026

• Other

UK biotech could be bound for recovery, BIA report reveals

pharminent April 27, 2026

• Regulatory

UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention

pharminent April 27, 2026

• M&A / Deals

Sun Pharma to acquire Organon for $11.75bn

pharminent April 27, 2026

• M&A / Deals

Sun sets out $11.75bn takeover play for Organon

pharminent April 27, 2026

• Gene Therapy

Gene therapy leaders aim to help more Baby KJs with novel regulatory models

pharminent April 27, 2026

• Regulatory

Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings

pharminent April 24, 2026

• Commercial

Daiichi Sankyo shares slip after delaying annual earnings report

pharminent April 24, 2026

• Pipeline

Pfizer culls early PD-L1 asset after series of clinical wins, deals in cancer

pharminent April 24, 2026

• M&A / Deals

Avalyn seeks public debut to support new lung drug formulations

pharminent April 24, 2026

• Commercial

Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels

pharminent April 24, 2026

• M&A / Deals

OZMOSI and Planview partner to enhance pharmaceutical data integration

pharminent April 24, 2026

• Clinical Data

Cardiometabolic trials: Using expertise to turn complexity into robust results

pharminent April 24, 2026

• Policy / Pricing

Regeneron cuts White House pricing deal, offers new gene therapy for free

pharminent April 24, 2026

• M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

pharminent April 24, 2026

• Regulatory

FDA clears first genetic hearing loss gene therapy

pharminent April 24, 2026

• M&A / Deals

Cumberland to sell drug portfolio to Apotex for $100m

pharminent April 24, 2026

• Regulatory

FDA approves Regeneron’s hearing loss gene therapy

pharminent April 23, 2026

• Regulatory

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

pharminent April 23, 2026

• Market Access

CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage

pharminent April 23, 2026

• Manufacturing

Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus

pharminent April 23, 2026

• Commercial

Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs

pharminent April 23, 2026

• Commercial

Sanofi posts upbeat sales as R&D pressure builds

pharminent April 23, 2026

• Pipeline

BBOT shakes up leadership as RAS competitors get more visibility

pharminent April 23, 2026

• Clinical Data

Novo says oral semaglutide works in diabetic kids

pharminent April 23, 2026

• Commercial

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

pharminent April 23, 2026

• Policy / Pricing

CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices

pharminent April 23, 2026

• Regulatory

Unnamed pharma files citizen petition targeting FDA’s trove of rejection letters

pharminent April 23, 2026

• Pipeline

Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

pharminent April 23, 2026

• Clinical Data

AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

pharminent April 23, 2026

• Policy / Pricing

Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care

pharminent April 23, 2026